Asset
Optimizer

Unlock optimal trial design parameters with comprehensive benchmarks linked to clinical trial success. Assess additional potential indications for your assets.

Portfolio optimizer

Get access to historic benchmarks on trial design for the last 20 years and compare how these correlated to success

Identify and assess promising indications to explore for a given asset

Portfolio optimizer

Customer Use Case

  • Objective
  • Intelligencia's Advantage
  • Impact
Download PDF

Objective

A top-10 pharmaceutical company had been developing a combination PD-1/chemotherapy treatment for melanoma. Phase 1 had been completed, and the team was looking into potential options for the Phase 2 program.

Previously, the company had relied on its own expertise, input from KOLs, and clinical trial consultants (to compile, for example, relevant benchmarks related to trial design). The internal R&D analytics team was also performing simulations on trial design.

Objective

A top-10 pharmaceutical company had been developing a combination PD-1/chemotherapy treatment for melanoma. Phase 1 had been completed, and the team was looking into potential options for the Phase 2 program.

Previously, the company had relied on its own expertise, input from KOLs, and clinical trial consultants (to compile, for example, relevant benchmarks related to trial design). The internal R&D analytics team was also performing simulations on trial design.

Intelligencia's Advantage

Intelligencia’s Asset Optimizer runs predictive analytics and sensitivity analyses on hundreds of parameters to enable users to build trial design scenarios testing key drivers such as:

  • Use of endpoints
  • Patients (number, inclusion/exclusion criteria)
  • Number of arms
  • Use of biomarkers
Further, it enables users to review analogues and benchmarks in a fast, systematic, consistent manner. Users can create their own benchmark views, applying filters on:

  • Timeline
  • Indication and TA
  • Modality, target, MoA
  • Phase, line of treatment

Impact

+25%

Increase in the probability of phase transition by refining the choice of endpoints and the number of arms in the Phase 2 program

+60%

Faster assessment of sensitivity scenarios compared to other methods

+40%

Additional parameters that can be assessed through sensitivity scenarios with our platform
Download PDF